Krystexxa is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Horizon Therapeutics Usa, Inc.. The primary component is Pegloticase.
| Product ID | 75987-080_1e58fd0e-5de0-4da4-a6cc-b6de4bcc275f |
| NDC | 75987-080 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Krystexxa |
| Generic Name | Pegloticase |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2010-09-14 |
| Marketing Category | BLA / BLA |
| Application Number | BLA125293 |
| Labeler Name | Horizon Therapeutics USA, Inc. |
| Substance Name | PEGLOTICASE |
| Active Ingredient Strength | 8 mg/mL |
| Pharm Classes | Urate Oxidase [CS], Uric Acid-specific Enzyme [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2010-09-14 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA125293 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2010-09-14 |
| Ingredient | Strength |
|---|---|
| PEGLOTICASE | 8 mg/mL |
| SPL SET ID: | 6e566303-d93a-4130-b764-25749829aa95 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 54396-801 | Krystexxa | pegloticase |
| 60809-801 | Krystexxa | pegloticase |
| 75987-080 | Krystexxa | pegloticase |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() KRYSTEXXA 77552516 3920201 Live/Registered |
HORIZON PHARMA RHEUMATOLOGY LLC 2008-08-21 |